Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of SEIKAGAKU CORPORATION. A complete text table follows the diagram.
Domestic drug growth and resilient LAL diagnostics cushion a royalty reset while the company invests in the next hyaluronan products.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Pharmaceutical | 1 | 12.1B | 67.7% of reported total |
| LAL | 1 | 5.8B | 32.3% of reported total |
| Other & rounding | 1 | 1M | 0.0% of reported total |
| Revenues From External Customers | 2 | 17.9B | Reported six-month total · ¥17.9B |
| Operating loss | 2 | 557M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 18.5B | Revenue plus reported operating loss |
| Profit before tax | 4 | 361M | Reported pretax result |
| Glycoscience funds the next product cycle | 4 | 18.1B | Domestic specialty drugs and LAL testing products support the base while royalties reset and R&D stays heavy. |
| Net profit attributable to owners | 5 | 229M | Reported parent-company result |
| Tax, attribution & other | 5 | 132M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Pharmaceutical | Revenues From External Customers | 12.1B |
| LAL | Revenues From External Customers | 5.8B |
| Other & rounding | Revenues From External Customers | 1M |
| Revenues From External Customers | Operating costs & expenses | 17.9B |
| Operating loss | Operating costs & expenses | 557M |
| Operating costs & expenses | Profit before tax | 361M |
| Operating costs & expenses | Glycoscience funds the next product cycle | 18.1B |
| Profit before tax | Net profit attributable to owners | 229M |
| Profit before tax | Tax, attribution & other | 132M |